SCHEMBL24253644

SCHEMBL24253644

O=C1CCCC2(CCN(c3cc(N4CCCOCC4)ncn3)CC2)N1c1ccc(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELOVL1 Q9BW60 2/20 0.41
RAD51 Q06609 1/20 0.38
RAB9A P51151 2/20 0.36
EGFR P00533 1/20 0.36
ERBB3 P21860 1/20 0.36
KMO O15229 1/20 0.35
P4HTM Q9NXG6 4/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP2C19 P33261 1/20 0.34
DPP4 P27487 3/20 0.34
PIK3CB P42338 1/20 0.34
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
NPC1 O15118 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30424148 1.00 ELOVL1 (0.41) ELOVL1RAD51RAB9AEGFRERBB3
SCHEMBL24253866 0.84 HCRTR1 (0.35) RAD51DPP4HTR1ADRD2ADRA1D
SCHEMBL30423985 0.84 HCRTR1 (0.35) RAD51DPP4HTR1ADRD2ADRA1D
SCHEMBL24253950 0.83 GPR119 (0.36) ELOVL1CYP2C19
SCHEMBL24253832 0.82 HCRTR2 (0.33) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253834 0.81 HCRTR1 (0.33) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL30423217 0.81 MOGAT2 (0.33) DPP4
SCHEMBL24253836 0.81 MOGAT2 (0.33) DPP4
SCHEMBL24253540 0.81 HCRTR1 (0.34) DPP4HTR1ADRD2ADRA1DADRA1A
SCHEMBL24253865 0.81 DPP4 (0.35) RAB9ASMN1; SMN2DPP4HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof NOVARTIS AG (CH) 2023-07-25 US disclosed
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708366-B2 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof REN, NR3C2, PKD1 ELOVL1 4619/4885RAD51 3303/4885RAB9A 1355/4885
US-20220048909-A1 HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF REN, NR3C2, PKD1 ELOVL1 4619/4885RAD51 3303/4885RAB9A 1355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.